TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30260780
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy added to sedation
Study: 30260780
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music treatment (control group)
Study: 27790965
Drug: Practice cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice cochlear implant surgery on different specimens for four weeks
Study: 27790965
Drug: Practice cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice cochlear implant surgery on the same specimen for four weeks
Study: 26574755
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (SB) 0.3 g∙kg‐1BM
Study: 20595158
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment with heated humidification
Study: 20595158
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment with sham‐heated humidification
Study: 12667663
Drug: IFN-beta 1a
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta 1a therapy
Study: 10738212
Drug: HAI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI group (5‐fluorouracil (5‐FU) 500 mg/day for 4 days followed by a 3‐day rest, continued for 6 weeks)
Study: 3303926
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B plus flucytosine (0.3 mg/kg per day of amphotericin B and 150 mg/kg per day of flucytosine) for four weeks
Study: 3303926
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B plus flucytosine (0.3 mg/kg per day of amphotericin B and 150 mg/kg per day of flucytosine) for six weeks
Study: 3303926
Drug: Flucytosine initial
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flucytosine initial dosing recommendations
Study: 31050312
Drug: Daily footbath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily footbath with alkaline soap
Study: 31050312
Drug: Daily footbath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily footbath with acidic soap
Study: 17157802
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (80 mg zinc oxide, 2 mg cupric oxide)
Study: 12361201
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol (100 microg)
Study: 2572652
Drug: Hydroxyzine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 50 mg
Study: 53172
Drug: Highly dosed
Normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly dosed organo-heparinoid ointment and gel
Study: 434431
Drug: R 33812
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 33812 4 mg i.v. before anaesthesia
Study: 434431
Drug: R 33812
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 33812 8 mg i.v. before anaesthesia
Study: 434431
Drug: R 33812
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 33812 10 mg orally with premedication
Study: 434431
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg orally as premedication
Study: 28209505
Drug: Conservative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatments plus gabapentin (group GPN)
Study: 23798746
Drug: DOWN -
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOWN - 45 minutes of physical therapy + 30 minutes of treadmill with 5% descending slope
Study: 23798746
Drug: UP -
Normalized name: SALICYLIC ACID 5 mg in 1 mL TOPICAL LIQUID [Neutrogena SkinClearing Oil Free Makeup - Buff 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP - 45 minutes of physical therapy + 30 minutes of treadmill with 5% ascending slope
Study: 17418538
Drug: Guided discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided discontinuation strategy
Study: 15194574
Drug: Prednisolone 7
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 7 mg/day
Study: 7621570
Drug: Nocturnal infusion
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal infusion of octreotide (1-1.5 micrograms/kg body weight, subcutaneously)
Study: 7621570
Drug: Nocturnal infusion
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal infusion of octreotide
Study: 2496951
Drug: Levonorgestrel (L‐NOG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (L‐NOG) 0.75 mg administered orally for 4 days during the periovulatory period (days 9, 11, 13, and 15)
Study: 2496951
Drug: Levonorgestrel (L‐NOG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (L‐NOG) 0.75 mg administered orally for 4 days during the periovulatory period (days 11, 12, 16, and 19)
Study: 2496951
Drug: Levonorgestrel (L‐NOG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (L‐NOG) 0.75 mg administered orally during the follicular or luteal phase
Study: 2496951
Drug: Levonorgestrel (L‐NOG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (L‐NOG) 0.75 mg administered orally during the follicular phase
Study: 2496951
Drug: Levonorgestrel (L‐NOG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (L‐NOG) administered during treatment
Study: 1264926
Drug: Aspirin B.P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin B.P. 300 mg
Study: 1264926
Drug: Claradin 150
Normalized name: Claradin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claradin 150 mg
Study: 1264926
Drug: Aspirin B.P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin B.P. 75 mg
Study: 1264926
Drug: Aloxiprin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloxiprin 300 mg
Study: 1264926
Drug: Claradin 50
Normalized name: Claradin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claradin 50 mg daily for 12-15 days
Study: 1264926
Drug: Claradin 25
Normalized name: Claradin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claradin 25 mg daily
Study: 31902567
Drug: iTBS (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTBS (intermittent theta burst stimulation) over the DLPFC for four weeks (20 daily sessions, 900 pulses per day)
Study: 28820793
Drug: Codeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (30 mg) plus acetaminophen (500 mg) orally 4 times per day for 4 days after PRK
Study: 26253644
Drug: Internet-delivered acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered acceptance and commitment therapy (iACT)
Study: 19278731
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg Zn/day)
Study: 19278731
Drug: Imipramine (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (approximately 140 mg/day) + Zinc supplementation
Study: 19278731
Drug: Imipramine (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (approximately 140 mg/day) + Placebo
Study: 15290454
Drug: Long-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-term low-dose daily 14-membered-ring macrolide therapy
Study: 15290454
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no macrolide therapy)
Study: 9519356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LHRH agonist buserelin (nasal spray) and cyproterone acetate (Androcur), either continuously or for the first 2 weeks
Study: 8128920
Drug: Lentinan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan (2 mg weekly for inpatients and 4 mg every other week for outpatients)
Study: 2475954
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (5 mg/kg body-weight infused over 30 minutes)
Study: 1020050
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adriamycin, vincristine and methotrexate (AVM)
Study: 1020050
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vinblastine, bleomycin and mithramycin (VBM)
Study: 31628359
Drug: Manual infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual infusion (MI)
Study: 31628359
Drug: Pump infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pump infusion (PI)
Study: 19874444
Drug: Buffered esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered esomeprazole (BE) 40 mg twice daily
Study: 19874444
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg bolus
Study: 17551145
Drug: Carboplatin-based chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based chemotherapy in patients with nonsquamous tumors
Study: 17551145
Drug: Carboplatin-based chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based chemotherapy in patients treated with third-generation chemotherapy
Study: 10088798
Drug: G-test (graded-exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-test (graded-exercise treadmill test, 3 km/hr; increase in grade of 3.5% every 3 minutes)
Study: 7585843
Drug: augmented betamethasone
Normalized name: Augmented betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: augmented betamethasone dipropionate 0.05% lotion
Study: 7585843
Drug: clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: clobetasol propionate 0.05% solution
Study: 2209315
Drug: MaxEPA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxEPA (10 g/day)
Study: 6996928
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg tablets, 4 times daily)
Study: 31244434
Drug: Co-ultraPEALut (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-ultraPEALut (1 mg/kg o.s.) administered 1h before LPS injection or 1h and 6h after LPS injection or 1h before LPS injection and 1h and 6h after LPS
Study: 31244434
Drug: Glialia® (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glialia® (700 mg PEA + 70 mg luteolin)
Study: 28728956
Drug: Ataluren (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren (40 mg/kg per day, orally, three times daily)
Study: 28728956
Drug: Ataluren (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren (40 mg/kg per day)
Study: 26056125
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg pSDF-1
Study: 26056125
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pSDF-1
Study: 25230350
Drug: control, physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: control, physiological normal saline solution
Study: 25230350
Drug: control, physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: control, physiological normal saline and epinephrine solutions
Study: 22437659
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy alone
Study: 22559159
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy + Amlodipine (calcium channel blocker)
Study: 22559159
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy + Valsartan (angiotensin receptor blocker)
Study: 19712037
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine and HZ
Study: 17726086
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (200 mg im every other week for 90 days)
Study: 26957281
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg/day)
Study: 12503776
Drug: Octa-60 5
Normalized name: Nonylphenol octa(oxyethylene) ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octa-60 5 mg/day
Study: 12503776
Drug: Octa-60 10
Normalized name: Nonylphenol octa(oxyethylene) ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octa-60 10 mg/day
Study: 9583201
Drug: Hyperglycemia during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia during induction therapy
Study: 7535267
Drug: Process-oriented treatment
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process-oriented treatment (POR chi) approach
Study: 1626663
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration of 3 micrograms.ml‐1
Study: 9640121
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration of 4 micrograms.ml‐1
Study: 1626663
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration of 5 micrograms.ml‐1
Study: 1626663
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentrations (3, 4, 5 micrograms.ml‐1)
Study: 29130400
Drug: EBCT-R (Exposure-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBCT-R (Exposure-Based Cognitive Therapy for depression)
Study: 23712210
Drug: CBT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT (Cognitive Behavioral Therapy)
Study: 30509345
Drug: Traditional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional radiation therapy
Study: 24764581
Drug: Primaquine (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (inhibitor of endosomal recycling)
Study: 23254461
Drug: Standardized Korean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Korean ginseng berry (SKGB, 350 mg ginseng berry extract per tablet)
Study: 8261826
Drug: Intraduodenal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal administration of 1 g/hr of fat
Study: 8261826
Drug: Intraduodenal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal administration of 2 g/hr of fat
Study: 27376872
Drug: RTG/EZG 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTG/EZG 600 mg/day
Study: 27376872
Drug: RTG/EZG 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTG/EZG 900 mg/day
Study: 22292673
Drug: Intratympanic (IT)
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic (IT) steroid and hyperbaric oxygen (HBO) therapy
Study: 22292673
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) steroid and hyperbaric oxygen (HBO) therapy
Study: 15647927
Drug: APC8015 (Provenge)
Normalized name: Provenge
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC8015 (Provenge) - an investigational therapeutic vaccine using autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase.
Study: 8162730
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of albuterol and theophylline
Study: 8162730
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (ipratropium, theophylline, and albuterol)
Study: 9136944
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups
Study: 8162730
Drug: Theophylline and
Normalized name: theophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline and albuterol
Study: 3065739
Drug: monthly intensive
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: monthly intensive CHOP treatment
Study: 31199458
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (2.5 mg, total of four oral bolus doses over four months)
Study: 31199458
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2.5 mg, total of four oral bolus doses over four months)
Study: 27463071
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - alternative and routine physical therapy or usual care
Study: 15286526
Drug: Total monthly
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total monthly cost per woman
Study: 8989344
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d oral phylloquinone
Study: 8989344
Drug: 2.5 mg/d
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/d oral phylloquinone
Study: 8515098
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg)
Study: 2971562
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.125 mg) inhaled
Study: 2971562
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug, seated position)
Study: 24127924
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment alone
Study: 19514614
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg once daily (in CORD IA)
Study: 19514614
Drug: ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 5 mg (n = 1,926)
Study: 19514614
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg (n = 1,887)
Study: 11499504
Drug: Two-implant overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant overdenture treatment
Study: 11499504
Drug: Four-implant overdenture
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-implant overdenture treatment
Study: 29693749
Drug: Various designs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various designs for examining treatment outcomes
Study: 26311549
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation and biofeedback treatment
Study: 26861425
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% cream
Study: 1318486
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 micrograms, inhaled)
Study: 26340545
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of CD133+ bone marrow stem cells
Study: 24268614
Drug: Cognitive Narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Narrative Therapy (CNT)
Study: 24268614
Drug: Cognitive Narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Narrative Therapy (CNT) and Cognitive‐Behavioral Therapy (CBT)
Study: 20421000
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of combination therapy
Study: 9671836
Drug: Oral electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral electronic thermometer
Study: 7719091
Drug: Intraperitoneal perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal perfusion of compound injection of Salvia Miltiorrhiza before closing the abdominal cavity and Dachengqi decoction orally post-operatively
Study: 7719091
Drug: Antibiotics intraperitoneally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics intraperitoneally before closing the abdominal cavity
Study: 2680475
Drug: Five or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five or more cups of coffee daily for 4 weeks
Study: 2680475
Drug: Five or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five or more cups of decaffeinated coffee daily for 4 weeks
Study: 59627
Drug: 5-azacytidine (200-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-azacytidine (200-250 mg/m2/day X 5 i.v.)
Study: 59627
Drug: guanazole (25-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanazole (25-30 g/m2/day X 5 continuous i.v. infusion)
Study: 31351345
Drug: Twice-weekly clinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly clinic visits
Study: 31351345
Drug: Weekly clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly clinic visits
Study: 19691545
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (waitlist control)